What are the symptoms of RSV and who is eligible for a vaccine? - RSV might at first seem like a cold but it can quickly ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Health officials have warned that people need to be protected against respiratory syncytial virus (RSV) by the vaccine.

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

It is a potentially fatal virus that can lead to hospitalisations and death in infants, but also in elderly and chronically ill adults. Two RSV vaccines were approved for use in Australia last ...

Respiratory syncytial virus ... and adults with chronic obstructive pulmonary disease and congestive heart failure. Despite more than 50 years of research, there are no RSV vaccines approved ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...

Respiratory infections are on the rise and infectious disease experts in the Lehigh Valley are advising community members to take caution to avoid catching any of the viruses circulating this winter.

pointing to low vaccine use in adults. In its release this morning, Shionogi made a similar point, noting that “effective antiviral treatment options for RSV remain limited, and there continues ...